Research location
Torres Vedras
Lisbon District, Portugal
Advertisement
Research activity in Torres Vedras
Lisbon District, PortugalCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Torres Vedras
8 linked trials · page 1 of 1A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisNCT06887192 · 2025-08-15 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)NCT06976203 · 2025-07-21 · 1 site observation
RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)NCT06585787 · 2024-09-26 · 1 site observation
RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)NCT05980949 · 2023-07-11 · 1 site observation
RECRUITING
Effectiveness of a 3-month Individual Reminiscence Therapy Program in Older Adults With Alzheimer's DiseaseNCT06812442 · 2025-02-01 · 1 site observation
COMPLETED
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.NCT04990284 · 2021-11-29 · 1 site observation
COMPLETED
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseNCT03131453 · 2017-08-03 · 1 site observation
TERMINATED
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic BronchitisNCT00656747 · 2008-03-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.